

CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE.....	7
A. GENERAL PRINCIPLES AND PROCEDURES	7
1. Background.....	7
2. Objective and scope.....	8
3. Selection of agents for review	9
4. Data for the <i>Monographs</i>	9
5. Meeting participants	10
6. Working procedures.....	11
B. SCIENTIFIC REVIEW AND EVALUATION	12
1. Exposure data.....	13
2. Studies of cancer in humans.....	14
3. Studies of cancer in experimental animals.....	18
4. Mechanistic and other relevant data.....	21
5. Summary	24
6. Evaluation and rationale.....	25
References.....	29
GENERAL REMARKS	31
ALOE VERA.....	37
1. Exposure Data.....	37
1.1 Identification of the agent	37
1.2 Analysis	43
1.3 Use.....	46
1.4 Production, sales, and consumption.....	47
1.5 Occupational exposure	51
1.6 Regulations and guidelines	51

2. Cancer in Humans	51
3. Cancer in Experimental Animals	51
3.1 Studies of carcinogenicity	51
3.2 Photo-co-carcinogenicity studies	52
4. Mechanistic and Other Relevant Data	55
4.1 Absorption, distribution, metabolism, and excretion	55
4.2 Genetic and related effects	57
4.3 Toxic effects and other mechanistic data	63
4.4 Other mechanistic data	64
4.5 Susceptibility	64
4.6 Mechanistic considerations	64
5. Summary of Data Reported	65
5.1 Exposure data	65
5.2 Human carcinogenicity data	66
5.3 Animal carcinogenicity data	66
5.4 Mechanistic and other relevant data	66
6. Evaluation	66
6.1 Cancer in humans	66
6.2 Cancer in experimental animals	67
6.3 Overall evaluation	67
References	67

GOLDENSEAL	73
1. Exposure Data	73
1.1 Identification of the agent and its major constituents	73
1.2 Analysis	75
1.3 Use	75
1.4 Production, sales, and consumption	77
1.5 Occupational exposure	78
1.6 Regulations and guidelines	78
2. Cancer in Humans	78
3. Cancer in Experimental Animals	78
3.1 Mouse	78
3.2 Rat	78
4. Mechanistic and Other Relevant Data	80
4.1 Absorption, distribution, metabolism, and excretion	80
4.2 Genetic and related effects	82
4.3 Other mechanistic data relevant to carcinogenicity	84
4.4 Susceptibility	84
4.5 Mechanistic considerations	84
5. Summary of Data Reported	85
5.1 Exposure data	85
5.2 Human carcinogenicity data	85
5.3 Animal carcinogenicity data	85
5.4 Mechanistic and other relevant data	85

6. Evaluation.....	86
6.1 Cancer in humans.....	86
6.2 Cancer in experimental animals.....	86
6.3 Overall evaluation.....	86
References.....	86
GINKGO BILOBA.....	91
1. Exposure Data.....	91
1.1 Identification of the agent.....	91
1.2 Analysis.....	95
1.3 Uses.....	96
1.4 Production, sales, and consumption.....	96
1.5 Occupational exposure.....	97
1.6 Regulations and guidelines.....	97
2. Cancer in Humans.....	97
2.1 Background.....	97
2.2 Randomized controlled trial.....	98
2.3 Case-control studies.....	98
3. Cancer in Experimental Animals.....	102
3.1 Mouse.....	102
3.2 Rat.....	105
4. Mechanistic and Other Relevant Data.....	105
4.1 Absorption, distribution, metabolism, and excretion.....	105
4.2 Genetic and related effects.....	108
4.3 Other mechanistic data relevant to carcinogenicity.....	109
4.4 Susceptibility.....	110
4.5 Mechanistic considerations.....	110
5. Summary of Data Reported.....	110
5.1 Exposure data.....	110
5.2 Human carcinogenicity data.....	110
5.3 Animal carcinogenicity data.....	111
5.4 Mechanistic and other relevant data.....	111
6. Evaluation.....	111
6.1 Cancer in humans.....	111
6.2 Cancer in experimental animals.....	111
6.3 Overall evaluation.....	111
References.....	112
KAVA.....	117
1. Exposure Data.....	117
1.1 Identification of the agent.....	117
1.2 Analysis.....	120
1.3 Use.....	120
1.4 Production, sales, and consumption.....	123
1.5 Occupational exposure.....	125
1.6 Regulations and guidelines.....	125

2. Cancer in Humans	125
3. Cancer in Experimental Animals	126
3.1 Mouse	126
3.2 Rat	126
4. Mechanistic and Other Relevant Data	128
4.1 Absorption, distribution, metabolism, and excretion	128
4.2 Genetic and related effects	130
4.3 Other mechanistic data relevant to carcinogenesis	135
4.4 Susceptibility	135
4.5 Mechanistic considerations	136
5. Summary of Data Reported	136
5.1 Exposure data	136
5.2 Human carcinogenicity data	136
5.3 Animal carcinogenicity data	136
5.4 Mechanistic and other relevant data	136
6. Evaluation	137
6.1 Cancer in humans	137
6.2 Cancer in experimental animals	137
6.3 Overall evaluation	137
References	137
PULEGONE.....	141
1. Exposure Data	141
1.1 Identification of the agent	141
1.2 Production and use	142
1.3 Occurrence and exposure	142
1.4 Regulations and guidelines	143
2. Cancer in Humans	143
3. Cancer in Experimental Animals	143
3.1 Mouse	143
3.2 Rat	145
4. Mechanistic and Other Relevant Data	145
4.1 Absorption, distribution, metabolism, and excretion	145
4.2 Genetic and related effects	149
4.3 Other mechanistic data	149
4.4 Susceptibility	151
4.5 Mechanistic considerations	151
5. Summary of Data Reported	151
5.1 Exposure data	151
5.2 Human carcinogenicity data	152
5.3 Animal carcinogenicity data	152
5.4 Mechanistic and other relevant data	152
6. Evaluation	152
6.1 Cancer in humans	152
6.2 Cancer in experimental animals	152
6.3 Overall evaluation	152
References	152

METHYLENE BLUE	155
1. Exposure Data	155
1.1 Chemical and physical data	155
1.2 Analysis	156
1.3 Production and use	156
1.4 Occurrence and exposure	162
1.5 Regulations and guidelines	162
2. Cancer in Humans	164
3. Cancer in Experimental Animals	164
3.1 Mouse	164
3.2 Rat	164
4. Mechanistic and Other Relevant Data	165
4.1 Absorption, distribution, metabolism, and excretion	165
4.2 Genetic and related effects	168
4.3 Other relevant mechanisms	176
4.4 Susceptibility	177
4.5 Mechanistic considerations	177
5. Summary of Data Reported	178
5.1 Exposure data	178
5.2 Human carcinogenicity data	178
5.3 Animal carcinogenicity data	178
5.4 Mechanistic and other relevant data	178
6. Evaluation	179
6.1 Cancer in humans	179
6.2 Cancer in experimental animals	179
6.3 Overall evaluation	179
References	179
PRIMIDONE	185
1. Exposure Data	185
1.1 Identification of the agent	185
1.2 Analysis	186
1.3 Production and use	186
1.4 Occurrence and exposure	189
1.5 Regulations and guidelines	190
2. Cancer in Humans	190
2.1 Cohort studies	190
2.2 Nested case-control studies	191
3. Cancer in Experimental Animals	193
3.1 Mouse	193
3.2 Rat	194
4. Mechanistic and Other Relevant Data	194
4.1 Absorption, distribution, metabolism, and excretion	194
4.2 Genetic and related effects	199
4.3 Other mechanistic data relevant to carcinogenesis	201
4.4 Susceptibility	202
4.5 Mechanistic considerations	202

5. Summary of Data Reported	203
5.1 Exposure data	203
5.2 Human carcinogenicity data	203
5.3 Animal carcinogenicity data	203
5.4 Mechanistic and other relevant data	203
6. Evaluation	204
6.1 Cancer in humans	204
6.2 Cancer in experimental animals	204
6.3 Overall evaluation	204
References	204

SULFASALAZINE	209
1. Exposure Data	209
1.1 Identification of the agent	209
1.2 Production	210
1.3 Occurrence and exposure	214
1.4 Regulations and guidelines	215
2. Cancer in Humans	215
2.1 Background	215
2.2 Longitudinal, cohort, and nested case–control studies	215
2.3 Case–control studies	221
2.4 Meta-analysis	222
3. Cancer in Experimental Animals	222
3.1 Mouse	222
3.2 Rat	224
3.3 Studies of co-carcinogenicity	226
4. Mechanistic and Other Relevant Data	226
4.1 Absorption, distribution, metabolism, and excretion	226
4.2 Genetic and related effects	233
4.3 Other mechanistic data relevant to carcinogenicity	239
4.4 Susceptibility	241
4.5 Mechanistic considerations	241
5. Summary of Data Reported	242
5.1 Exposure data	242
5.2 Human carcinogenicity data	242
5.3 Animal carcinogenicity data	243
5.4 Mechanistic and other relevant data	243
6. Evaluation	244
6.1 Cancer in humans	244
6.2 Cancer in experimental animals	244
6.3 Overall evaluation	244
References	244

PENTOSAN POLYSULFATE SODIUM.....	251
1. Exposure Data	251
1.1 Chemical and physical data.....	251
1.2 Analysis	252
1.3 Production.....	252
1.4 Occurrence and exposure.....	255
1.5 Regulations and guidelines	255
2. Cancer in Humans	255
3. Cancer in Experimental Animals	255
3.1 Mouse.....	255
3.2 Rat	256
4. Mechanistic and Other Relevant Data	257
4.1 Absorption, distribution, metabolism, and excretion	257
4.2 Genetic and related effects	258
4.3 Other mechanistic data relevant to carcinogenicity	259
4.4 Susceptibility	260
4.5 Mechanistic considerations.....	260
5. Summary of Data Reported	260
5.1 Exposure data.....	260
5.2 Human carcinogenicity data.....	260
5.3 Animal carcinogenicity data.....	260
5.4 Mechanistic and other relevant data.....	260
6. Evaluation.....	261
6.1 Cancer in humans	261
6.2 Cancer in experimental animals.....	261
6.3 Overall evaluation	261
References.....	261
TRIAMTERENE.....	263
1. Exposure Data	263
1.1 Chemical and physical data.....	263
1.2 Analysis	264
1.3 Production and use.....	264
1.4 Occurrence and exposure.....	268
1.5 Regulations and guidelines	268
2. Cancer in Humans	268
2.1 Background.....	268
2.2 Triamterene and cancer of the breast	271
2.3 Combined use of triamterene and hydrochlorothiazide, and cancer of the lip	271
2.4 The drug class including triamterene, and cancer of the breast or colorectum	271
3. Cancer in Experimental Animals	272
3.1 Mouse.....	272
3.2 Rat	274

4. Mechanistic and Other Relevant Data	274
4.1 Absorption, distribution, metabolism, and excretion	274
4.2 Genetic and related effects	277
4.3 Other mechanistic data relevant to carcinogenicity	277
4.4 Susceptibility	278
4.5 Mechanistic considerations	279
5. Summary of Data Reported	279
5.1 Exposure data	279
5.2 Human carcinogenicity data	279
5.3 Animal carcinogenicity data	280
5.4 Mechanistic and other relevant data	280
6. Evaluation	280
6.1 Cancer in humans	280
6.2 Cancer in experimental animals	280
6.3 Overall evaluation	280
References	281

HYDROCHLOROTHIAZIDE	285
1. Exposure Data	285
1.1 Identification of the agent	285
1.2 Analysis	286
1.3 Production and use	286
1.4 Occurrence and exposure	290
1.5 Regulations and guidelines	290
2. Cancer in Humans	290
2.1 Cancers of the lip and skin	291
2.2 Renal cell carcinoma	301
2.3 Other cancers	302
3. Cancer in Experimental Animals	304
3.1 Oral administration	304
3.2 Coexposure with modifying agents	306
4. Mechanistic and Other Relevant Data	306
4.1 Absorption, distribution, metabolism, and excretion	306
4.2 Genetic and related effects	310
4.3 Other mechanistic data relevant to carcinogenicity	312
4.4 Susceptibility	312
4.5 Mechanistic considerations	312
5. Summary of Data Reported	312
5.1 Exposure data	312
5.2 Human carcinogenicity data	312
5.3 Animal carcinogenicity data	313
5.4 Mechanistic and other relevant data	314
6. Evaluation	314
6.1 Cancer in humans	314
6.2 Cancer in experimental animals	314
6.3 Overall evaluation	314
References	314

PIOGLITAZONE AND ROSIGLITAZONE	319
1. Exposure Data	319
1.1 Chemical and physical data on pioglitazone	319
1.2 Analysis of pioglitazone	321
1.3 Production and use of pioglitazone	321
1.4 Occurrence and exposure to pioglitazone	326
1.5 Regulations and guidelines for pioglitazone	326
1.6 Chemical and physical data on rosiglitazone	327
1.7 Analysis of rosiglitazone	328
1.8 Production and use of rosiglitazone	328
1.9 Occurrence and exposure to rosiglitazone	329
1.10 Regulations and guidelines for rosiglitazone	330
2. Cancer in Humans	331
2.1 Cancer of the bladder	339
2.2 Cancer of the liver	351
2.3 Cancer of the colorectum	351
2.4 Cancer of the lung	352
2.5 Cancer of the prostate	353
2.6 Cancer of the breast	353
2.7 Other site-specific cancers	353
3. Cancer in Experimental Animals	354
3.1 Pioglitazone	354
3.2 Rosiglitazone	357
4. Mechanistic and Other Relevant Data	361
4.1 Absorption, distribution, metabolism, and excretion of pioglitazone	361
4.2 Absorption, distribution, metabolism, and excretion of rosiglitazone	362
4.3 Genetic and related effects	364
4.4 Other mechanistic data	366
4.5 Susceptibility	369
4.6 Mechanistic considerations	369
5. Summary of Data Reported	371
5.1 Exposure data	371
5.2 Human carcinogenicity data	371
5.3 Animal carcinogenicity data	372
5.4 Mechanistic and other relevant data	373
6. Evaluation	373
6.1 Cancer in humans	373
6.2 Cancer in experimental animals	373
6.3 Overall evaluation	373
References	373

DIGOXIN	381
1. Exposure Data.....	381
1.1 Chemical and physical data.....	381
1.2 Analysis.....	383
1.3 Production and use.....	383
1.4 Occurrence and exposure.....	390
1.5 Regulations and guidelines.....	390
2. Cancer in Humans.....	390
2.1 Cancer of the breast.....	391
2.2 Cancers of the uterus and ovary.....	396
2.3 Cancer of the prostate.....	399
2.4 Non-Hodgkin lymphoma.....	399
2.5 Other cancer sites.....	403
3. Cancer in Experimental Animals.....	403
4. Mechanistic and Other Relevant Data.....	403
4.1 Absorption, distribution, metabolism, and excretion.....	403
4.2 Genetic and related effects.....	410
4.3 Other mechanistic data relevant to carcinogenicity.....	410
4.4 Susceptibility.....	411
4.5 Mechanistic considerations.....	412
5. Summary of Data Reported.....	412
5.1 Exposure data.....	412
5.2 Human carcinogenicity data.....	412
5.3 Animal carcinogenicity data.....	413
5.4 Mechanistic and other relevant data.....	413
6. Evaluation.....	414
6.1 Cancer in humans.....	414
6.2 Cancer in experimental animals.....	414
6.3 Overall evaluation.....	414
References.....	414
LIST OF ABBREVIATIONS	421

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

